source
- Gilead reports modest sales rise but analysts question future growth beyond HIV drugsGilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
- AL Sydbank discloses share transactions by managers and related persons under MARAL Sydbank issued a company announcement (No 41/2026) on 5 August 2026, informing the market of share transactions carried out by its managers and persons closely associated with them. The disclos…